Deals

ElevenLabs Wants Another $500 Million. A Better Voice Is Only the Beginning.

The next advantage will come from completing customer work and securing usable rights. Both demand more than a convincing voice.

Vincent JiangVincent Jiangfive-minute read
Share
ElevenLabs co-founder Mati Staniszewski speaking at an event in 2022
Mati Staniszewski, ElevenLabs' co-founder, predicted last October that AI audio models would become commodities.

*September 17, 2026 | Approximately 6 minutes*

The founder saw the price pressure coming

Mati Staniszewski predicted last October that AI audio models would become commodities. 1

Now ElevenLabs~$3.3B — ElevenLabs, private, latest valuation ~$3.3B is reportedly seeking more than $500 million, with the EU-backed Scaleup Europe Fund in investment talks. The September 17 report describes negotiations, not a completed financing. Its confirmed February round raised $500 million at an $11 billion valuation. 2, 3

The apparent contradiction explains the strategy. A company expecting more competition in its core technology must build something customers cannot replace by swapping one model for another. For ElevenLabs, that means moving deeper into the work around the voice: customer service, business systems, deployment support and licensed creative content.

By May, ElevenLabs said annual recurring revenue exceeded $500 million, up from roughly $350 million at 2025's end. 4

$0M$100M$200M$300M$400M$500MEnd of 2025~$350MMay 2026>$500M
Data
Value
End of 2025~$350M
May 2026>$500M
ElevenLabs' reported annual recurring revenue, unaudited and annualized. Source: TechCrunch, May 2026.4

Those are unaudited annualized figures, not a year's collected revenue. They establish commercial momentum. They do not establish how much profit survives the cost of serving increasingly demanding customers.

The fight is over who owns the customer relationship

Consider a caller trying to reset an account password. A natural voice helps the conversation start. The useful product must also identify the person, follow the company's rules, change the right record and transfer the call when it cannot proceed.

ElevenLabs' workflow documentation already describes tool execution, branching and transfers to human agents. That shows where its product is moving. The functions are available; their existence does not prove every deployment works reliably. 5

The commercial threat comes from both sides. Amazon's−3.93% — Amazon, down 3.93 percent today Nova 2 Sonic documentation describes a speech system integrated with Amazon Connect, placing a competing model beside an existing contact-center product. Alibaba's−0.85% — Alibaba, down 0.85 percent today Qwen3-TTS offers commercially permissive model weights that developers can run themselves. Neither establishes a cheaper finished deployment, but both expand the buyer's choices. 6, 7

That creates two different risks. A cloud provider can bundle speech into software the customer already buys. A technically capable customer can replace a speech component while keeping its own workflow. ElevenLabs becomes harder to displace when replacing it means rebuilding a working operation, not just changing the voice.

The danger is that someone else owns that operation and treats ElevenLabs as a replaceable supplier.

The invoice reveals what enterprises actually buy

The public ElevenAgents rate card, checked September 17, prices additional call minutes at eight cents, with language-model and telephony charges billed separately. A five-minute additional call therefore produces a 40-cent platform call charge. That calculation excludes the rest of the deployment. 8

An unusually useful document comes from the Maryland Health Benefit Exchange. Its January procurement includes an enterprise order template with an $87,600 annual minimum: $4,300 a month committed to usage and $3,000 to a Success Package. Annualized, support accounts for approximately 41% of that minimum. These are template terms, not evidence of actual consumption. 9

  • Committed usage$51,60058.9%
  • Success Package$36,00041.1%
Data
SliceValueShare
Committed usage$51,60058.9%
Success Package$36,00041.1%
The Maryland Health Benefit Exchange template's $87,600 annual minimum, split between committed usage and the Success Package. Support is about 41% of the total. Source: Maryland Health Benefit Exchange procurement, January 2026.9

The voice wins the demonstration; the completed task earns the renewal.

The record exposes the work hidden behind a cheap minute. Customers need support, operating commitments and a system that fits existing processes. One procurement cannot describe ElevenLabs' entire customer base, but it demonstrates why multiplying minutes by an advertised price produces an incomplete business case.

That is both an opportunity and a cost. Support can help retain customers and command a premium. If each new customer requires extensive bespoke work, however, revenue can grow faster than the economics improve. The important question is how much deployment work becomes reusable as the customer base expands.

Music brings permission, but does not guarantee exclusivity

The same logic applies to ElevenLabs' creative business. Generating audio is one capability. Giving a business clear permission to use it is another.

The September 10 agreement with Universal Music Group concerns a new licensed music platform that remains in development. Reporting published September 15 established that it is separate from existing ElevenMusic products; ElevenLabs also confirmed that Music v2.5 had not trained on UMG artists' music. The new deal should not be mistaken for blanket rights across everything ElevenLabs already sells. 10

Permission can become a commercial advantage because customers need outputs they can actually deploy. But UMG had already announced a licensed-platform agreement with Udio in October 2025. The rights holder is building multiple relationships. ElevenLabs has a path to differentiated content, not demonstrated exclusive control over the market. 11

The financial terms of the ElevenLabs agreement remain undisclosed. 14 Rights may expand demand while adding another claim on the revenue. A famous catalog is an asset to the product; its value to shareholders depends on what the supplier must pay for access.

The strongest case for ElevenLabs

The bullish case deserves more than a dismissal about models becoming interchangeable. Enterprises often prefer buying a maintained system to assembling speech, reasoning, telephony, monitoring and support themselves. Lower model costs could expand that market and improve the economics of the complete product.

There is evidence of demand beyond demonstrations. April reporting on Customers Bank described an ElevenLabs agreement covering planned customer support, onboarding and employee coaching. Those are deployment plans, not proven savings, but they identify actual work a buyer wants done. 12

Deutsche Telekom's February CoMind announcement also places ElevenLabs inside a broader service combining knowledge retrieval, business workflows and human handoff. That supports the distribution case while exposing its limit: a partner can bring the customer and retain the broader relationship. 13

The stronger business would therefore be a system customers renew because it reliably completes work, with better voices improving an operation that is already embedded. Technical leadership helps win that position. It cannot substitute for it.

What the next renewal must prove

The next financing announcement will reveal how much capital investors are willing to supply. Customer renewals will reveal something more useful: whether ElevenLabs can retain spending as alternative voices become easier to obtain.

Watch deployment time, the cost of human escalation, repeat contacts after an allegedly resolved call, and profit after inference and support. For the music business, watch the licensed platform's launch, paying adoption and the share of revenue retained after rights payments.

Staniszewski does not need every model advantage to last forever. He needs the customer to have a reason to stay after the next convincing voice arrives.

Get Deals by email, free

The acquisitions, rounds and contracts that move AI money. In our daily email, every weekday.

Loading AMZN

Reader comments

0 comments

    Deals

    Anthropic's $81 billion IPO, the biggest ever, opened at $111.50 and left open buyers under water at $94.29

    The biggest IPO on record landed on the worst tape since spring, and DataTrek's tally of the 2026 class says debut-day entries usually lose. Public buyers paid the open while employees, founders and allocated institutions held from the offer price.

    Deals

    Salesforce agreed to pay $47.50 a share for Braze, whose SEC-filed FAQ leaves renewal terms undecided

    Three weeks after Salesforce agreed to buy Braze for $5.66 billion, the seller's own SEC-filed sales script promises enterprise buyers nothing beyond today's contracts while its account teams push multi-year renewals. For BRZE holders the stock is now a claim on $47.50 in cash, and the deal documents price the wait.

    Deals

    Musk puts a Tesla-SpaceX merger at 25% within a year

    Prediction-market odds put the announcement in early 2027, and the pay agreement Musk signed in 2025 lets a rich deal price vest shares no operating goal has earned. The cost lands on Tesla holders, who also own the deciding vote.

    Deals

    Sacramento votes to renew Axon for $17.7 million and bar AI training on city camera data

    The renewal makes Sacramento own its camera data, opt out of Axon's AI training and bar default sharing with federal agencies. Spread across renewals, those terms reach the data advantage beneath the software Axon's beaten-down stock now leans on.

    Deals

    Merck buys AI drug designs from Isomorphic Labs two days after its $5 billion round

    MSD, Merck & Co. (NYSE: MRK) outside the United States and Canada, carries the clinical and commercial risk and pays an undisclosed upfront, milestones and tiered royalties, while Isomorphic Labs holds a new option to co-fund trials for elevated royalties. Two days after the largest life-science venture round ever, the deal hands Alphabet's (Nasdaq: GOOGL) AI drug spinout its fourth Big Pharma payer before any candidate has entered a human trial.

    Deals

    AMD closed Taalas at $2.9 billion, with $1.4 billion riding on undisclosed milestones

    AMD's completion release named no price; the quarterly filing that carries the terms makes up to $1.4 billion of the $2.9 billion contingent on conditions the company has not disclosed. It is the second AI acquisition in a fortnight, about $11.1 billion combined, by a stock trading above 100 times trailing earnings.

    Subscribe to TheInference for free